ArticleCureus2024
Acute Vision Loss as the Sole Presenting Symptom of Posterior Reversible Encephalopathy Syndrome.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 45-year-old female with poorly controlled HTN presented with sudden, painless bilateral vision loss over 12 hours. On examination, she had only light perception in both eyes, with normal fundoscopy and no focal neurological deficits. Laboratory tests revealed mildly elevated creatinine and proteinuria. Imaging with MRI showed symmetrical hyperintensities in the occipital and parietal lobes, consistent with posterior reversible encephalopathy syndrome (PRES), while magnetic resonance angiography excluded large vessel occlusion. She was admitted to the intensive care unit, where blood pressure was controlled with intravenous labetalol, followed by oral antihypertensive therapy. Her vision improved within three days, and a repeat MRI on day five showed a resolution of the hyperintensities. The patient was discharged on day five with stable blood pressure and instructions for strict antihypertensive adherence. At a two-week follow-up, her visual acuity returned to baseline, and her serum creatinine normalized. This case emphasizes the importance of early diagnosis and management of PRES, particularly in patients with uncontrolled HTN, to prevent long-term neurological damage and recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.